JMI LABS IS NOW PART OF LEARN MORE

Activity of Meropenem-Vaborbactam and Comparators Against Enterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States

Activity of Meropenem-Vaborbactam and Comparators AgainstEnterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients

Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic
Fibrosis Patients. Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Prevalence, Phenotypic and Genotypic Characteristics, and Clinical Presentations of Staphylococcus argenteus Causing Bloodstream Infections in United States Hospitals

Prevalence, Phenotypic and Genotypic Characteristics, and Clinical Presentations of Staphylococcus argenteus Causing Bloodstream Infections in United States Hospitals. Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric Patients from US Medical Centers (2020–2021)

Antimicrobial Activity of Ceftazidime-Avibactam and Other New β-Lactamase Inhibitor Combinations Tested against Bacterial Isolates from Pediatric
Patients from US Medical Centers (2020–2021). Lead author: Helio Sader. IDWeek 2022. October 19-21. Washington DC.

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)

In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-21, Washington DC.

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021)

In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021). Lead Author: Michael Huband, IDWeek 2022, October 19-21, Washington DC.

Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017–2021)

Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017–2021). Lead author: Cecilia Carvalhaes, IDWeek 2022, October 18-21, Washington DC.

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents by Castanheira M, Deshpande LM, Mendes RE, Doyle TB, Sader HS in JAC-Antimicrob. Resist. 2022; 4(5): dlac098.

Activity of Meropenem/Vaborbactam and Comparators against non-carbapenemase producing carbapenem-resistant Enterobacterales isolates from Europe

Activity of Meropenem/Vaborbactam and Comparators against non-carbapenemase producing carbapenem-resistant Enterobacterales isolates from Europe by Shortridge D, Deshpande L, Streit J, and Castanheira M in JAC – Antimicrob. Resist. 2022; 4 (5): dlac097.

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019)

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019) by Pfaller MA, Mendes RE, Streit JM, Carvalhaes, CG in Diagnostic Microbiology and Infectious Disease 2022; 104: 115804.

Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020)

Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020) by Sader HS, Castanheira M, Carvalhaes CG, Arends SJR, Mendes RE in Microbial Drug Resistance 2022; 28 (9): 935-940.

Activity of Gepotidacin against Escherichia coli isolates from urinary tract infections collected between 2019-2021 from Germany and other European Countries

Activity of Gepotidacin against Escherichia coli isolates from urinary tract infections collected between 2019-2021 from Germany and other European Countries. Lead author: SJ Ryan Arends, presented by C Ress at German Society for Urology 2022, September 21-24, Hamburg, Germany

Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019)

Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019) by Carvalhaes CCG, Sader HS, Rhomberg PR, Castanheira M, DeVries S, Mendes RE in Pediatr. Infect. Dis. J. 41(9):2022, 731-735.

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018 by Shortridge D, Streit J, Pfaller M, Tulloch M, Chen WT, Castanheira M in J. Glob. Antimicrob. Resist. 31 (2022): 98-103.

Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme

Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme by Carvalhaes CG, Sader HS, Streit JM, Mendes RE in JAC-Antimicrob. Resist. 4(5): 2022, dlac088

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii by Michaeli J, Mandel S, Maximov S, Zazoun J, Savoia P, Kothari N, Valmont T, Ferrari L, Duncan LR, Hawser S, Cohen-Kutner M, Bachnoff N in antibiotics 11 (2022): 201.

Rezafungin In vitro Activity against Candida spp. causing Invasive Infections in Hematology/Oncology and Transplant Units Worldwide (2014-2021)

Rezafungin in vitro activity against Candida spp. causing invasive infections in hematology/oncology and transplant units worldwide (2014-2021). Lead Author: Cecilia Carvalhaes. Presented at International Immunocompromised Host Society (ICHS 2022), Basel, Switzerland, 8-11 September 2022.

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications by Rogers TR, Verweij PE, Castanheira M, Dannaoui E, White PL, Arendrup, MC on behalf of the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) in J. Antimicrob. Chemother. 10:2022, dkac61.

Azole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression

Azole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression by Castanheira M, Deshpande L, Davis A, Carvalhaes C, Pfaller M in J. Glob. Antimicrob. Resist. 29: 2022, 317-377.

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes

In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes by Mendes RE, Rhomberg, PR, Watters AA, Castanheira M in J. Antimicrob. Chemother. 77(3): 2022, 689-694.

Frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of Gram-negative and Gram-positive organisms via single-step mutational analysis

Frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of Gram-negative and Gram-positive organisms via single-step mutational analysis. Lead author: SJ Ryan Arends presented at ASM Microbe 2022, June 9-13, Washington DC

Ceftibuten-avibactam (fixed 4 μg/mL), ceftibuten, and ceftazidime-avibactam (fixed 4 μg/mL) broth microdilution quality control ranges using a CLSI M23 (2018) multi-laboratory study design

Ceftibuten-avibactam (fixed 4 μg/mL), ceftibuten, and ceftazidime-avibactam (fixed 4 μg/mL) broth microdilution quality control ranges using a CLSI M23 (2018) multi-laboratory study design. Lead Author: MD Huband presented at ASM Microbe 2022, June 9-13, 2022, Washington DC

 

Comparison of the VITEK2 Advanced Expert System phenotyping and genetic characterization of β-Lactamase Genes for Enterobacterales isolates from North and Latin America

Comparison of the VITEK2 Advanced Expert System phenotyping and genetic characterization of β-Lactamase genes for Enterobacterales isolates from North and Latin America. Lead author: CG Carvalhaes, presented at ASM Microbe 2022, June 9-13, Washington DC, USA

Poster #2427

The NCI and NIAID collaborative screen of the NPNPD Natural Product Fraction Library identified selective antimicrobial activity from natural source

The NCI and NIAID collaborative screen of the NPNPD Natural Product Fraction Library identified selective antimicrobial activity from natural source. Lead author: Leonard Duncan presented at ASM Microbe 2022, June 9-13, Washington DC

MIC predictions for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model

MIC predictions for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model presented by M Castanheira at ASM Microbe 2022, June 9-13, Washington DC

High-throughout screening of the Natural Product Discovery Fraction Library from the National Cancer Institute identified fractions with selective antimicrobial activity

High-throughout screening of the Natural Product Discovery Fraction Library from the National Cancer Institute identified fractions with selective antimicrobial activity presented by SJ Ryan Arends at ASM Microbe 2022, June 9-13, Washington DC.

Evaluation of bactericidal activity, post-antibiotic, and sub-inhibitory effect of gepotidacin against various Gram-negative and Gram-positive isolates

Evaluation of bactericidal activity, post-antibiotic, and sub-inhibitory effect of gepotidacin against various Gram-negative and Gram-positive isolates. Lead Author: SJ Ryan Arends presented at ASM Microbe 2022, June 9-13, Washington DC

Prediction of MIC values for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model

Prediction of MIC values for four β-lactam agents for Escherichia coli and Klebsiella pneumoniae from a large surveillance program using genomic data and a machine learning model. Lead author: Cory Hubler, presented at ASM Microbe 2022, June 9-13, Washington DC

In vitro activity of manogepix against 1,435 fungal isolates collected worldwide during the SENTRY surveillance program (2020)

In vitro activity of manogepix against 1,435 fungal isolates collected worldwide during the SENTRY surveillance program (2020). Lead Author: MD Huband presented at ASM Microbe 2022, June 9-13, 2022, Washington DC

Detection of the carbapenem-hydrolyzing CTX-M-15 variant, CTX-M-33, among carbapenem-nonsusceptible Klebsiella pneumoniae isolates from Poland

Detection of the carbapenem-hydrolyzing CTX-M-15 variant, CTX-M-33, among carbapenem-nonsusceptible Klebsiella pneumoniae isolates from Poland. Lead author Mariana Castanheira presented at ASM Microbe 2022, June 9-13, Washington DC

Comparison of MIC results for gepotidacin by agar dilution and broth microdilution methods for various Gram-positive and Gram-negative species

Comparison of MIC results for gepotidacin by agar dilution and broth microdilution methods for various Gram-positive and Gram-negative species. Lead author SJ Ryan Arends. Presented at ASM Microbe 2022, June 9-13, Washington DC

Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections

Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections by Pfaller MA, Carvalhaes CG, DeVries S, Rhomberg PR, Castanheira M in Med. Mycol. J. 2022; 6 (60): myac028.

In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072) against clinical isolates with molecularly characterized tetracycline resistance mechanisms

In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072) against clinical isolates with molecularly characterized tetracycline resistance mechanisms by Pfaller MA, Li L, Liu Q, Zhang J, Huband MD, Lindley JM, Mendes RE in J. Glob. Antimicrob. Resist. 3(4): 2021, dlab177.

In vitro potency and spectrum of the novel polymycin MRX-8 tested against clinical isolates of Gram-negative bacteria

In vitro potency and spectrum of the novel polymycin MRX-8 tested against clinical isolates of Gram-negative bacteria by Duncan LR, Wang W, Sader HS in Antimicrob. Agents Chemother. 2022; 66 (5): 10.1128.

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020

Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020 by Duncan LR, Hamed KA, Smart JI, Pfaller MA, Flamm RK, Mendes RE published in Diagn. Microbiol. Infect. Dis. 2022; 103: 115713.

Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing

Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing by Sader HS, Lindley J, Deshpande LM, Doyle T, Castanheria M. in Diagn. Microbiol. Infect. Dis. 2002; 103 (2) 115673.

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020) by Carvalhaes CG, Klauer AL, Rhomberg PR, Pfaller MA, Castanheira, M in J. Clin. Microbiol. 2022; 60 (4) doi: 10.1128/jcm.02449-21

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)

Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020) by Carvalhaes C, Klauer A, Rhomberg PR, Pfaller MA, Castanheira M in J. Clin. Microbiol. 2022; 60 (4), https://doi.org/10.1128/jcm.02449-21.

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020)

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020) by Sader, HS, Castanheira, M, Huband MD, Shortridge, D, Carvalhaes, CG, Mendes, RM in Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41, 867-873.

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. By Shortridge D, Streit JM, Mendes R, and Castanheira M published in Microbiol. Spectr. 2022; 10 (2),  e02712-21.

Antimicrobial Activity of Gepotidacin Against Recent Clinical Isolates of Escherichia coli Collected from Japan in 2019-2020

Antimicrobial Activity of Gepotidacin Against Recent Clinical Isolates of Escherichia coli Collected from Japan in 2019-2020. Lead author: SJ Ryan Arends. Japanese Association of Infectious Diseases (JAID) 22-23 April 2022.

Antimicrobial Activity of New Beta-Lactam/Beta-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units

Antimicrobial Activity of New Beta-Lactam/Beta-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa and Enterobacterales from Patients with Pneumonia in Intensive Care Units. Lead author: HS Sader presented at American Thoracic Society May 13-18, 2022, San Francisco, CA, USA

Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021)

Antimicrobial Activity of Dalbavancin and Comparators against Gram-positive Bacteria Causing Bacteraemia in Patients with Skin and Skin Structure Infections (2017-2021). Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal

Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)

Antimicrobial Susceptibility of Organisms Isolated from Complicated UTI in Europe: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021). Lead author: CG Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster # 1114

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021

Lefamulin Activity against Bacterial Pathogens Typically Causing Pneumonia Collected from European Medical Centres in 2020 and 2021. Lead author: HS Sader presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1119

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020)

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020). Lead author: RE Mendes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1163

Prevalence of Carbapenemases and Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Among a Global Collection of Enterobacterales

Prevalence of Carbapenemases and Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Among a Global Collection of Enterobacterales. Lead author: M Castanheira, presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #2164

Comparison Analysis of In vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infections in Europe and Surrounding Regions (2020)

Comparison Analysis of In vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infections in Europe and Surrounding Regions (2020). Lead author: RE Mendes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1158

Activity of Cefiderocol and Comparators against US isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020-2021)

Activity of Cefiderocol and Comparators against US isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020-2021). Lead author: D Shortridge presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1099

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific. Lead author: C Carvalhaes presented at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 23-26, 2022, Lisbon, Portugal
Poster #1148